GlassScriptPhysician profile
Heather L Wolf
NPI 1801824511
$6,987.71
in general payments reported to CMS, 2019-2025
22 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $577 · 2022: $1,666 · 2023: $1,627 · 2024: $1,810 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,445 · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,444.76 |
| Education | $299.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,009.21 | 2022-2025 | |
| Janssen Biotech, INC. | $988.57 | 2022-2025 | Tremfya |
| Incyte Corporation | $638.53 | 2022-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $618.53 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $507.96 | 2022-2024 | Sotyktu |
| Almirall LLC | $397.93 | 2021-2025 | Klisyri, Seysara |
| Pfizer INC. | $372.20 | 2022-2025 | |
| Genzyme Corporation | $367.12 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $321.35 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $319.07 | 2022-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $268.63 | 2021-2024 | Ilumya |
| Galderma Laboratories, L.P. | $243.91 | 2021-2023 | Aklief |
| Amgen INC. | $198.68 | 2023-2025 | Otezla, Enbrel, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $132.22 | 2021-2022 | |
| Dermavant Sciences, INC. | $124.75 | 2023-2024 | Vtama |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $104.94 | 2025 | Ebglyss |
| Ucb, INC. | $90.45 | 2024 | Bimzelx |
| Janssen Scientific Affairs, LLC | $86.45 | 2023 | Tremfya |
| Verrica Pharmaceuticals INC. | $80.25 | 2023-2024 | Ycanth |
| Ascensia Diabetes Care US INC. | $57.85 | 2023 | |
| Mayne Pharma Commercial LLC | $38.24 | 2023-2025 | |
| Biofrontera INC. | $20.87 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.